Indegene Shares Gain on Axis Securities' Bullish FY27 Outlook

Shares of Indegene climbed following Axis Securities' initiation of coverage on the Bengaluru-based pharmaceutical consulting and technology services company. The brokerage's research team highlighted that Indegene has entered fiscal 2027 with an expanded and more balanced growth pipeline, positioning the company favourably amid evolving market dynamics in the pharmaceutical and life sciences sectors.

According to the analysis, Indegene's growth trajectory is supported by sustained expansion within its existing client base, coupled with rising revenue contributions from new service verticals and client additions. This diversification of revenue sources is expected to provide greater resilience and stability to the company's earnings growth.

The initiation of coverage by a major brokerage house typically signals growing institutional interest in the stock and reflects confidence in the company's medium-term prospects. Axis Securities has assigned a target price reflecting its bullish medium-term outlook, though specific price targets and rating details were not disclosed in initial reports.

Indegene, which provides integrated pharmaceutical services spanning research, consulting, and digital solutions, has been benefiting from increased outsourcing by global pharmaceutical and biotechnology companies. The company's expanded capabilities and geographic reach have enhanced its competitive positioning in an industry experiencing sustained demand for specialized services.